NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $3,144 | -99.9% | 314,762 | 0.0% | 0.31% | +5.1% |
Q1 2023 | $2,795,087 | -19.1% | 314,762 | 0.0% | 0.29% | -31.3% |
Q4 2022 | $3,456,087 | -15.7% | 314,762 | 0.0% | 0.43% | -16.1% |
Q3 2022 | $4,101,000 | +2.8% | 314,762 | 0.0% | 0.51% | +10.4% |
Q2 2022 | $3,988,000 | -9.6% | 314,762 | 0.0% | 0.46% | +3.8% |
Q1 2022 | $4,410,000 | -51.6% | 314,762 | 0.0% | 0.44% | -48.0% |
Q4 2021 | $9,112,000 | -3.4% | 314,762 | 0.0% | 0.86% | +54.6% |
Q3 2021 | $9,430,000 | +12.9% | 314,762 | 0.0% | 0.55% | +15.0% |
Q2 2021 | $8,351,000 | -14.7% | 314,762 | 0.0% | 0.48% | -12.1% |
Q1 2021 | $9,786,000 | -5.4% | 314,762 | 0.0% | 0.55% | -2.5% |
Q4 2020 | $10,349,000 | -5.8% | 314,762 | 0.0% | 0.56% | -7.1% |
Q3 2020 | $10,988,000 | – | 314,762 | – | 0.60% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
AtonRa Partners | 24,227 | $190,424 | 0.40% |
WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |